海正药业及相关责任人收浙江证监局警示函

Core Viewpoint - The company, Haizheng Pharmaceutical, has received a warning letter from the Zhejiang Securities Regulatory Bureau due to inaccuracies in its financial disclosures for the years 2021-2024, which included corrections to revenue, costs, and investment income [2]. Group 1: Regulatory Actions - The Zhejiang Securities Regulatory Bureau issued a warning letter to Haizheng Pharmaceutical and several key personnel, including the former chairman and president, for violations of the Information Disclosure Management Measures [2]. - The company disclosed corrections to its financial data on August 26, 2025, indicating that previously reported financial information was not true or accurate [2]. Group 2: Financial Reporting Issues - The corrections involved significant financial metrics such as operating revenue, operating costs, and investment income, reflecting discrepancies in the company's financial reporting [2]. - The regulatory body emphasized that the actions taken by the company and its executives violated specific articles of the Information Disclosure Management Measures, leading to the issuance of the warning letter [2].